Collagen IV alpha 1 Antibody (1106301) [FITC]

• Reactivity: Hu
• Applications: IHC
• Clone: 1106301
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: FITC

Collagen IV alpha 1 Antibody (1106301) [FITC] Summary

• Description: This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.
  
  For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.
• Immunogen: Synthetic peptide
  Accession # P02462
• Specificity: Detects recombinant human COL4A1 protein in Direct ELISA.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
• Application Notes: Recommended applications are based on validated applications from the unconjugated base product MAB11758. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Purity: Protein A or G purified from hybridoma culture supernatant

Alternate Names for Collagen IV alpha 1 Antibody (1106301) [FITC]

• alpha-1 chain
• Arresten
• COL4A1 NC1 domain
• COL4A1
• collagen alpha-1(IV) chain
• Collagen IV alpha 1
• collagen IV, alpha-1 polypeptide
• collagen, type IV, alpha 1
• Collagen-4
• EC 3.4.23
• EC 6.3.1.2

Background

Collagen IV is well suited to detect extracellular matrix proteins in normal as well as disease state tissues. Disruption of tissue organization is the hallmark of neoplasia. Malignant lesions can be distinguished from benign by examining the breakdown of basement membranes and loss of 3-dimensional architecture. Malignant cells are presumed to use matrix metalloproteases to degrade barriers created by the extracellular matrix which then allows metastasis to occur. Collagenases, stomelysins and gelatinases can collectively degrade all of the various components of the extracellular matrix, including fibrillar and non-fibrillar collagens and basement membrane glycoproteins.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.